Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

NCT05995340 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05995340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05995340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Double-blind, Randomized, Parallel-group, Controlled Study to Evaluate the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
November 21, 2023
Completion date
July 14, 2026
Enrollment
157 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

atrophic acne scars